GlassScriptPhysician profile
Sandra J Lewis
NPI 1427040179
$12,295.36
in general payments reported to CMS, 2019-2025
15 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,757 · 2020: $59.04 · 2021: $3,648 · 2022: $99.00 · 2023: $154 · 2024: $345 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,288.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $3,855.20 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $3,535.24 | 2019-2025 | |
| Novo Nordisk INC | $199.18 | 2024 | Wegovy |
| Abiomed | $93.00 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $69.92 | 2019-2024 | Camzyos |
| Amgen INC. | $62.63 | 2020-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.85 | 2023-2025 | Lifevest |
| Amarin Pharma, INC. | $31.17 | 2019 | |
| Pfizer INC. | $25.27 | 2025 | |
| Cvrx, INC. | $23.48 | 2024 | Barostim Neo System |
| Lilly USA, LLC | $22.30 | 2025 | Zepbound |
| Boston Scientific Corporation | $21.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.74 | 2019 | |
| Preventice Services, LLC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.